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Abstract
Background: Intensified case finding (ICF) and earlier antiretroviral therapy (ART) initiation are strategies to reduce
burden of HIV-associated tuberculosis (TB). We describe incidence of and associated factors for TB among
HIV-positive individuals with CD4 counts > 350 cells/μl in South Africa.
Methods: Prospective cohort study of individuals recruited for a TB vaccine trial. Eligible individuals without
prevalent TB were followed up at 6 and 12 months after enrolment. Cox proportional hazards regression was used
to determine factors associated with risk of incident TB.
Results: Six hundred thirty-four individuals were included in the analysis [80.9 % female, 57.9 % on ART, median
CD4 count 562 cells/μl (IQR 466–694 cells/μl)]. TB incidence was 2.7 per 100 person-years (pyrs) (95 % CI 1.6–4.4 per
100 pyrs) and did not differ significantly between those on ART and those not on ART [HR 0.65 (95 % CI 0.24–1.81)].
Low body mass index (BMI <18.5 kg/m2) was associated with incident TB [HR 3.87 (95 % CI 1.09–13.73)]. Half of the
cases occurred in the first 6 months of follow up and may have been prevalent or incubating cases at enrolment.
Conclusions: TB incidence was high and associated with low BMI. Intensified case finding for TB should be
strengthened for all HIV positive individuals regardless of their CD4 count or ART status.
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Background
Tuberculosis (TB) remains a public health concern in
high HIV prevalence settings. In 2013, the World Health
Organisation (WHO) estimated that in South Africa,
62 % of individuals newly diagnosed with TB were HIV
positive [1]. Failure to address HIV-associated TB will
result in failure to achieve the global targets for TB con-
trol or elimination [2].
The increase in the risk of TB associated with HIV oc-
curs early in the course of HIV infection and increases
rapidly as the CD4 count decreases [3–5]. The initiation
of antiretroviral therapy (ART) in HIV-positive individ-
uals should theoretically decrease the risk of TB
regardless of CD4 count. The restoration of TB specific
immunity with ART use is known to be incomplete and
variable such that HIV-positive individuals on ART re-
main at elevated risk of TB compared to HIV negative
persons. Restoration in TB specific immunity has been
shown to be poorer among individuals with lower nadir
CD4 counts [6, 7]. Initiating ART at higher CD4 counts
(>350cells/μl) has been shown to reduce TB incidence
[8, 9]. South Africa recently announced an increase in
the cut-off for ART initiation to 500 cells/μl, [10] largely
for its benefits in reducing HIV- related morbidity and
HIV transmission [11]. The latest guidance moved the
country towards implementation of the universal test
and treat approach, which will see all HIV-positive indi-
viduals being eligible for ART regardless of CD4 count.
The objective of this study was to assess the incidence of
TB in a cohort of HIV positive individuals with CD4
counts ≥350 cells/μl, assess factors associated with risk
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of incident TB and discuss the implications for TB pre-
vention. The study was originally set-up to determine
baseline incidence for future TB vaccine trials among
HIV- positive persons, but could also provide useful in-
formation for programme strategies.
Methods
Location and setting
Between June 2011 and June 2012, consecutive HIV-
positive adults attending care at two primary care facil-
ities in Gauteng Province, South Africa were invited to
participate in a TB vaccine preparedness study including
HIV- positive individuals with a recent CD4 counts >
300cells/μl. This cut-off was selected to match the inclu-
sion criteria for TB vaccine trials including HIV-positive
individuals at the time. In this secondary analysis we
present data on the incidence of TB among a subset of
participants with confirmed CD4 counts > 350 cells/μl.
The anticipated TB vaccine trial intended to enrol indi-
viduals who were aged between 18 and 45 years of age,
had a documented HIV positive result with CD4 count >
350 cells/μl, were healthy and independently able to
carry out activities of daily living, willing and able to
avoid pregnancy or elective surgery during the trial and
able to complete study procedures and follow up. Add-
itional criteria for inclusion in the vaccine preparedness
study were : i) having a documented CD4 count >
300cells/μl in the 12 months preceding enrolment re-
gardless of whether or not they were taking ART, ii) and
be living or working in the communities surrounding
the clinics.
Study population and procedures
Study- specific recruiters identified individuals as they
registered for HIV care and referred them to a study
nurse located in a different part of the clinic for assess-
ment of eligibility to enrol in the study. The study nurse
enrolled eligible and consenting individuals and adminis-
tered a questionnaire collecting data on demographic
characteristics, history of previous exposure to or treat-
ment for TB, history of HIV care and treatment (includ-
ing ART) and presence of symptoms suggestive of TB
[cough, fever, night sweats or weight loss of any dur-
ation]. Participants had their heights and weights mea-
sured and were asked to provide a blood specimen for
CD4 count testing. Female participants were asked to
provide a urine specimen in order to exclude pregnancy.
Participants who reported symptoms suggestive of TB
were also asked to provide two sputum specimens for
smear microscopy and mycobacterial culture and had a
chest radiograph done in order to exclude TB at enrol-
ment (see Additional files 1, 2, 3 and 4). The chest radio-
graphs were sent to a single radiologist who read them
using a standardized tool and determined if the chest
radiograph findings were likely to be a result of active
TB (see Additional file 4).
As this study was planned to estimate TB incidence
among participants who would be eligible for a TB vac-
cine trial, participants who were pregnant, were on TB
treatment, or diagnosed with TB at enrolment or whose
enrolment culture results came back positive were not
eligible for inclusion and follow-up. Those eligible for
follow up were invited to return for study visits at 6 and
12 months after enrolment. At each follow up visit, the
study nurse administered a questionnaire enquiring
about TB diagnoses, ART, isoniazid preventive therapy
(IPT), cotrimoxazole preventive therapy (CPT) initiation
and symptoms suggestive of TB. If at follow up, partici-
pants reported symptoms suggestive of TB, they had
sputum specimens collected for smear microscopy and
culture and sent for a chest radiograph to exclude TB
(see Additional files 5 and 6). Participants who missed
follow up visits were contacted by telephone and re-
quested to come for follow up. If the participants could
not be reached, their next of kin were contacted using
contact details provided by participants at enrolment. At
the next of kin contact, the study team enquired about
vital status and if alive about alternative contact details of
the participant. The study team also independently
reviewed the HIV clinic records of all participants and ab-
stracted data on TB and HIV care in order to verify some
self- reported data. Completed study questionnaires were
couriered to a central data management centre and data
entered into a study specific database. Data were exported
into STATA® 12.0 (College Station, Texas, USA) for ana-
lysis. Study follow up procedures were conducted until
March 2013 (see Additional files 7 and 8).
Data analysis
Participants who were pregnant, taking TB treatment, or
had TB diagnosed at enrolment or within the first
3 months of enrolment were excluded from the second-
ary analysis as were those who had CD4 counts < 350
cells/μl. Participants included were described using me-
dians and interquartile ranges for continuous variables
and proportions for categorical variables, comparing
those on ART with those not on ART at enrolment.
Follow-up time (person-years of follow-up) was deter-
mined from date of enrolment until diagnosis of TB,
death, or date of last study visit, whichever occurred
first. Incident TB was defined as having a documented
TB treatment initiation by the clinic or having a positive
sputum smear or culture or a chest radiograph consist-
ent with active TB at a study follow up visit. The TB in-
cidence estimates were determined and compared for
participants on ART with those not on ART. Partici-
pants who initiated ART during follow up contributed
person- time to both on ART and not on ART groups.
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Univariable and multivariable Cox proportional hazards
regression were used to determine factors associated with
incident TB in follow up. Because of the small number of
outcomes a maximum of two variables with the smallest
p-values under 0.2 in univariable analyses were included
the multivariable model with being on ART included a
priori. A subgroup analysis excluding participants who re-
ported TB symptoms at enrolment was conducted in
order to determine effect of TB screening on incident TB.
Results
Study population
Of 2191 participants assessed for eligibility to enrol, 839
were enrolled and 634 were included in this secondary
analysis (see Fig. 1). Of the 1352 not eligible for enrol-
ment, the majority were excluded because of low CD4
counts at eligibility assessments. Among those enrolled,
a further 205 were excluded from analysis because of du-
plicate enrolments (n = 5), undocumented ART status at
enrolment (n = 4), taking TB treatment at enrolment (n
= 15), being diagnosed with TB at enrolment or in the
first 3 months of follow up (n = 16), pregnant at enrol-
ment (n = 34), having CD4 counts <350 cells/μl (n = 71)
and 60 did not return for any follow up visits and could
not be traced.
Among the 634 participants included in the analysis,
19.1 % were male, median age was 36.1 years (IQR 29.8–
42.1), 38 (6.0 %) had BMI < 18.5 kg/m2, median CD4
count was 562 cells/μl (IQR 466–694) and 367 (57.9 %)
had been taking ART for a median of 2.0 years (IQR
1.0–3.9 years) at enrolment. Participants on ART were
slightly older [37.4 years (IQR 31.4–42.3 years) vs.
33.5 years (IQR 28.8–40.8 years) p < 0.002], more likely
to have been treated for TB in the past [31.3 % vs.
19.5 %, p < 0.001] but less likely to report current or
prior IPT use at enrolment [13.9 % vs. 35.6 %, p < 0.001]
(Table 1).
Incidence of TB during follow up
The 634 participants included in the analysis were
followed up for a median of 11.2 months (IQR
8.8 months–12.4 months) and contributed 565 person-
years at risk during follow up. Due to budgetary con-
straints, follow up had to be limited to 8 months post
enrolment for last participant enrolled. During the fol-
low up period, 15 participants were diagnosed with TB,
three died and 18 who were not on ART at enrolment
initiated ART. Among the 15 individuals who had inci-
dent TB, 10 had pulmonary TB [four smear positive,
four were smear negative, culture positive, two were
smear negative diagnosed by chest radiograph], one
extra-pulmonary TB and remaining four were self-
reported by participants but site of disease and smear
status not verified with clinic records. The median time
to TB diagnosis was 6 months (IQR 3.3–8.3 months).
The overall TB incidence rate was 2.7 per 100 person-
years (pyrs) (95 % CI 1.6–4.4 per 100 pyrs) and did not
differ between participants on ART and those not on
ART [2.2 per 100 pyrs (95 % CI 1.0–4.5 per 100 pyrs) vs.
3.4 per 100 pyrs (95 % CI 1.6–7.0 per 100 pyrs)] (see
Table 2). Among 224 participants who were on ART and
had CD4 counts > 500 cells/μl at enrolment, there were
five incident TB cases in 208 pyrs of follow up giving an
incidence rate 2.4 per 100 pyrs (95 % CI 1.0–5.8 per 100
pyrs) while among the 159 participants not on ART at
enrolment, there were three TB cases in 127 pyrs giving
also an incidence of 2.4 per 100pyrs (95 % CI 0.8- 7.3
per 100 pyrs).
Fig. 1 Study flow
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Factors associated with incident TB in follow up
Table 2 shows findings from univariable and multivari-
able analyses of factors associated with incident TB in
follow up. In univariable analyses, having a low body
mass index (BMI) [HR 3.93 (95 % CI 1.11–13.92), p =
0.034] was the only factor which was significantly associ-
ated with the risk of incident TB. In the multivariable
model adjusting for the effect being on ART and low
BMI, having a low BMI remained independently associ-
ated with the risk of incident TB [HR 3.87 (95 % CI
1.09–13.73). All variables in the model met the propor-
tional hazards assumption.
In a sub-group analysis which excluded participants
who reported TB symptoms at enrolment, there were nine
incident TB cases in 482 pyrs of follow up. The TB inci-
dence in this group was 2.1 per 100 pyrs (95 % CI 1.1–4.1
per 100 pyrs). The TB incidence seemed lower among par-
ticipants on ART compared to when they were not on
ART [1.5 per 100 pyrs (95 % CI 0.5- 3.7 per 100 pyrs) vs
3.4 per 100 pyrs (95 % CI 0.5–3.9 per 100 pyrs) although
confidence intervals overlapped. In univariable analyses,
being on ART remained associated with a statistically in-
significant trend towards lower risk of TB compared to
not being on ART [HR 0.43 (95 % CI 0.11–1.60), p =
0.207] while having a low BMI was associated with a sta-
tistically insignificant trend towards higher risk of TB [HR
2.87 (95 % CI 0.36–23.11), p = 0.322]. Because of a low
number of outcomes, multivariable analyses were not con-
ducted for this sub-group analysis.
Discussion
In this secondary analysis, the overall incidence of TB
among participants with CD4 counts > 350 cells/μl was
high. Low BMI was independently associated with in-
creased incidence of TB while being on ART was not as-
sociated with risk of incident TB in this population.
Neither CD4 count level nor duration since HIV testing
was associated with increased risk of incident TB.
Our finding of increased risk of TB among those with
low BMI supports findings from previous studies. BMI
has been shown to be a good predictor of both prevalent
and incident TB among HIV positive individuals and
among the general population [12–14]. It is also a pre-
dictor of mortality and poorer outcomes among HIV posi-
tive individuals diagnosed with TB [15, 16]. This finding
suggests that BMI calculation may be included in TB
screening and diagnostic algorithms in order to increase
sensitivity of existing algorithms. More research is needed
on how best to include BMI in TB screening algorithms.
Within HIV clinic settings, patients with high CD4
counts represent newly diagnosed individuals with
higher CD4 counts and those who may have initiated
ART at lower CD4 counts but have reconstituted their
immune system to higher CD4 count levels. The TB in-
cidence estimate from this analysis were comparable to
the 2-3 cases per 100 person-years reported among simi-
lar cohorts but higher than the general population rate
estimated to be 1000 cases per 100 000 population [13,
17–19]. ART is one of the most effective tools for pre-
venting TB among individuals with HIV. However the
effectiveness of ART as a tool for preventing TB is lim-
ited by the CD4 count levels and by the extent to which
ART restores TB specific immune responses. Earlier ini-
tiation of ART prevents CD4 count decline and might
preserve TB specific immune responses [6, 7]. The high
rates of TB among those who had not initiated ART
Table 1 Characteristics of cohort at enrolment (N = 634)
Characteristic All ART (n = 367) not on ART (267)
Males (n, %) 121 (19.1) 67 (18.3) 54 (20.2)
Age in years (median, IQR) 36.1 (29.8–42.1) 37.4 (31.4–42.3) 33 (28.8–40.8)
Employment (n, %) 254 (40.1) 156 (42.5) 98 (36.7)
Ever smoked (n, %) 143 (22.3) 90 (24.5) 53 (19.8)
Currently drink alcohol (n, %) 251(41.4) 152 (41.4) 99 (37.1)
Duration since HIV test years€ (median, IQR) 1.8 (0.8–4.4) 2.5 (1.4–4.9) 1.1 (0.4–2.4)
Duration on ART years (median, IQR) - 2.0 (1–3.9) -
Current or prior INH use (n, %) 146 (23) 51 (13.9) 95 (35.6)
Current CPT use (n, %) 94 (14.8) 36 (9.8) 58 (21.7)
Previous TB treatment (n, %) 167 (26.3) 115 (31.3) 52 (19.5)
TB symptoms at enrolment (n, %) 152 (24) 76 (20.7) 76 (28.5)
CD4 count at enrolment (median, IQR)β 562 (466–694) 546 (466–688) 575 (456–716)
CD4 counts > 500 cells/μl (n, %) 383 (60.4) 224 (61) 159 (60)
BMI (median, IQR)α 24.4 (21.3–27.8) 24.5 (20.1–27.1) 24.5 (21.5–28.4)
€- available for 446 participants (253 on ART and 193 not on ART), β-available for 588 participants (342 on ART and 246 not on ART), α- available for 621
participants (356 on ART and 265 not on ART
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therefore support the need for earlier initiation of ART
as a tool to prevent TB. Additional interventions such as
TB screening, isoniazid preventive therapy and TB infec-
tion control are also needed to complement the ART.
Not being on ART is a known risk factor for the devel-
opment of opportunistic infections even at high CD4
counts, [9, 20, 21]. The individual and population-level
impact of earlier ART initiation on TB incidence and
outcomes is being investigated in trials of the universal
test and treat [22, 23].
Half the incident TB cases occurred in the first
6 months of follow up suggesting they may have been
prevalent or incubating cases at enrolment (although in-
dividuals diagnosed in the first 3 months were consid-
ered as prevalent TB). This finding highlights the
continued need for intensified case finding at high CD4
counts regardless ART status [24]. Studies have sug-
gested that the four symptom TB screening algorithm
may be less sensitive and specific among individuals tak-
ing ART and receiving regular screening for TB [25, 26].
There is need to develop more sensitive and specific
symptom screening algorithms that best identify individ-
uals who require further evaluation for TB.
This analysis is based on a study which identified and
enrolled participants with high CD4 counts in order to
estimate TB incidence. We included a sub-group analysis
excluding participants who reported symptoms at enrol-
ment and likely excluded most prevalent TB at enrol-
ment. However our analysis also had some limitations.
Firstly the study had strict inclusion criteria for entry
into the study. These criteria were necessary because the
study was meant to be a TB vaccine preparedness study
Table 2 Factors associated with incident TB during follow up [15 TB cases among 634 participants in 565 person-years of follow up]
Variable Category TB cases Person-years
of follow up
Incidence per 100
person years (95 % CI)






Total population 15 565 2.7 (1.6–4.4)
Gender Female 13 458 2.8 (1.6–4.9) 1
Male 2 107 1.9 (0.5–7.4) 0.66 (0.15–2.91) 0.560
Age <35 years 6 258 2.3 (1.0–5.2) 1
≥35 years 9 307 2.9 (1.5–5.6) 1.27 (0.45–3) 0.649
Employed No 11 338 3.3 (1.8–5.9) 1
Yes 4 227 1.8 (0.7–4.7) 0.53 (0.17–1.68) 0.264
Ever smoked No 10 440 2.3 (1.2–4.2) 1
Yes 5 125 4.0 (1.7–9.6) 1.76 (0.60–5.14) 0.322
Currently drink alcohol No 8 341 2.3 (1.2–4.7) 1
Yes 7 224 3.1 (1.5–6.5) 1.32 (0.48–3.64) 0.593
Duration since HIV test ≥ 2 years 6 193 3.1 (1.4–6.9) 1 0.905
<2 years 5 207 2.4 (1.0–5.8) 0.78 (0.24–2.57)
missing 4 164 2.4 (0.9–6.9) 0.79 (0.22–2.82)
On ART No 7 209 3.4 (1.6–7.0) 1 1
Yes 8 356 2.2 (1.1–4.5) 0.65 (0.24–1.81) 0.461 0.68 (0.18–1.82) 0.458
Current or prior INH use No 12 446 2.7 (1.5–4.7) 1
Yes 3 119 2.5 (0.8–7.8) 0.95 (0.27–3.36) 0.930
Current CPT use No 12 464 2.5 (1.4–4.4) 1
Yes 3 81 3.7 (1.2–11.4) 1.48 (0.42–5.26) 0.557
Previous TB treatment No 10 416 2.4 (1.3–4.5) 1
Yes 5 149 3.4 (1.4–8.1) 1.40 (0.48–4.10) 0.545
CD4 count ≥500 cells/μl 8 335 2.4 (1.2–4.8) 1
350–500 cells/μl 6 184 3.3 (1.5–7.3) 1.35 (0.47–3.89) 0.828
missing 1 47 2.1 (0.3–15.2) 0.86 (0.11–6.90)
BMI category ≥18.5 kg/m2 12 521 2.3 (1.3–4.1) 1 1 0.036
<18.5 kg/m2 3 32 9.4 (3.0–29.1) 3.93 (1.11–13.92) 0.034 3.87 (1.09–13.73)
missing 0 12 0 - 1
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aimed at estimating incidence in populations that would
be eligible for vaccine trials. The strict criteria may limit
the extent to which findings are generalizable to other
settings. Our study population was 80 % female likely as
a result of the high CD4 count requirement which more
women are likely to have from earlier diagnosis, linkage
and retention in care [27–30]. Since rates were high in
this population, we expect them to be higher in popula-
tions with lower CD4 counts. Secondly we had a limited
sample size and duration of follow up. Because the inci-
dence of TB decreases with increasing duration on ART,
the shorter duration of follow up may have overesti-
mated overall TB incidence in this cohort. Thirdly, be-
cause of budgetary constraints, there was sub-optimal
follow up of participants in the study and most incident
cases were diagnosed by the clinics. As a result we may
have under ascertained the true number of TB cases in
the study population. However both clinics had access
to smear microscopy, culture and (at a later stage of the
study) Xpert MTB/Rif and were able to refer individuals
for chest radiographs and diagnosis of extra-pulmonary
TB as part of routine TB and HIV care. This minimised
the under-ascertainment of incident cases. The small
number of outcomes meant very few variables could be
included in multivariable cox proportional hazards re-
gression models to adjust for confounding. Despite these
limitations the study contributes relevant cohort data on
the incidence of TB in an important population.
Conclusion
The incidence of TB was high in this population of HIV
positive individuals with relatively high CD4 counts. In-
tensified case finding needs to be strengthened regard-
less of CD4 count or ART status.
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